drugset / Trial / NCT06995625
The STem Cell-derived Extracellular Vesicle Therapy In Acute Ischemic Stroke (STEVIA)
NaSingle-groupOpen-labelTreatment
Summary
This is a multicenter open-label, single-arm, dose escalation phase I clinical trial to evaluate the safety and tolerability of SNE-101 in patients with acute ischemic stroke
Timeline
- Start
- 2026-06-22
- Primary completion
- 2027-03-31
- Completion
- 2027-03-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | SNE-101 | Other / unclassified | 4.8e+10 unknown | Intravenous |
| Subject | SNE-101 | Other / unclassified | 9.6e+10 unknown | Intravenous |
| Subject | SNE-101 | Other / unclassified | 1.92e+11 unknown | Intravenous |